UK Cancer Drugs Fund Debuts To Muted Applause From Pharma, Charities
The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation.
You may also be interested in...
The Innovative Medicines Fund is not delivering the ambition that was set out when it was launched in England last year, according to one UK company general manager.
NICE has given the go-ahead for routine NHS commissioning of seven cancer drugs/indications that were listed on the Cancer Drugs Fund before it was overhauled earlier this year. A total of 35 product indications are up for reappraisal under the program.
On the basis of its experience with Halaven, Eisai is predicting that its kidney cancer drug Kisplyx will face a difficult journey getting the OK from NICE, England's health technology appraisal institute.